• Publications
  • Influence
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.
Reduced-intensity or nonmyeloablative stem cell transplantation (NST) is designed to induce host-versus-graft tolerance by engraftment of donor stem cells. The rationale behind NST is to induceExpand
  • 198
  • 8
Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Allogeneic bone marrow transplantation (BMT) is the treatment of choice for hematologic malignancies resistant to conventional chemotherapy and for patients who are at high risk for relapse. UntilExpand
  • 203
  • 7
Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients.
Induction of protective hemagglutination-inhibition (HI) antibodies in response to influenza virus vaccine and the effectiveness of two doses versus a single dose of vaccine were studied in 48 BMTExpand
  • 153
  • 7
PET-CT of extranodal lymphoma.
1579 ymphoma, mainly non-Hodgkin’s lymphoma, may be extranodal in origin in approximately 40% of patients. Extranodal involvement may also be due to regional spread of nodal disease or hematogenousExpand
  • 72
  • 6
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (abmt) for malignant lymphoma (ml). allogeneic transplantation (allosct) is a therapeuticExpand
  • 175
  • 5
The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation
The chemokine stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, participate in the retention of acute myeloblastic leukemia (AML) cells within the bone marrow microenvironment and theirExpand
  • 87
  • 5
Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.
Allogeneic bone marrow transplantation (BMT) is the only effective treatment for hematologic malignancies resistant to conventional chemotherapy. Until recently, no cure existed for patients whoExpand
  • 376
  • 4
T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of
One hundred and forty‐six patients with acute leukaemia (81 with ANLL and 65 with ALL) received allogeneic bone marrow transplantation from their fully matched siblings. 121 patients underwent T‐cellExpand
  • 119
  • 4
Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma
Background:  18Fluoro‐2‐deoxyglucose (18FDG) positron emission tomography (PET) is widely used for initial staging and follow‐up in patients with malignant lymphoma. While earlier studies suggested aExpand
  • 99
  • 4
Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation
Viral infection has been shown to induce aplastic anemia, unidentified types of hepatitis being the most common cause for aplastic anemia-associated viral hepatitis. The survival rate for this groupExpand
  • 69
  • 4